The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients

Kidney International

Volumn 64, Issue 1, 2003, Pages 295-304

  Tonelli, Marcello ^b   Winkelmayer, Wolfgang C ^b   Jindal, Kailash K ^b   Owen Jr , William F ^b   Manns, Braden J ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b NONE

Author keywords

Cost; Cost effectiveness analysis; Economic evaluation; Erythropoietin; Hemodialysis

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ANEMIA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; HEALTH CARE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0038806683     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00079.x     Document Type: Article

References (42)

1. HSU CY, MCCULLOCH CE, CURHAN GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510, 2002
2. COLADONATO JA, FRANKENFIELD DL, REDDAN DN, et al: Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 13:1288-1295, 2002
3. COLLINS AJ, LI S, ST. PETER W, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
4. COLLINS AJ, LI S, EBBEN J, et al: Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36:282-293, 2000
5. COLLINS AJ, MA JZ, EBBEN J: Impact of hematocrit on morbidity and mortality. Semin Nephrol 20:345-349, 2000
6. MA JZ, EBBEN J, XIA H, et al: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
7. NKF-K/DOQI: Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37 (Suppl 1):S182-S238, 2001
8. TOFFELMIRE EB, BARRETT BJ, FENTON SS, et al: Clinical practice guidelines for the management of anemia coexistent with chronic renal gailure. J Am Soc Nephrol 10:S287-S321, 1999
9. EUROPEAN BEST PRACTICE GUIDELINES FOR THE MANAGEMENT OF ANAEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE: Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 14(Suppl 5):1-50, 1999
10. HIRTH RA, CHERNEW ME, MILLER E, et al: Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20:332-342, 2000
11. United States Renal Data System (USRDS) Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
12. CANADIAN ERYTHROPOIETIN STUDY GROUP: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300:573-578, 1990
13. BESARAB A, ASLAM M: Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients? Yes! Blood Purif 19:168-174, 2002
14. SONNENBERG FA, BECK JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
15. GOLD MR, SIEGEL JE, RUSSELL LB, WEINSTEIN M: Cost Effectiveness in Health and Medicine, New York, Oxford University Press, 1996
16. MANNS BJ, JOHNSON JA, TAUB KJ, et al: Quality of Life in Patients with End-Stage Renal Disease on Hemodialysis or Peritoneal Dialysis: What Are the Important Determinants?, Edmonton, Canada, Institute of Health Economics, 2002
17. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
18. FOLEY RN, PARFREY PS, MORGAN J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
19. HYNES DM, STROUPE KT, GREER JW, et al: Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 112:169-175, 2002
20. Drug Topics Red Book, Montvail, NJ, Medical Economics Company Incorporated, 2001
21. United States Renal Data System (USRDS) Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999
22. LEE J, MANNS BJ, TAUB KJ, et al: Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 40:611-622, 2002
23. LAUPACIS A, KEOWN P, PUS N, et al: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50:235-242, 1996
24. XIA H, EBBEN J, MA JZ, et al: Hematocrit levels and hospitalization risks in hemodialysis patients. J Ant Soc Nephrol 10:1309-1316, 1999
25. GOLAN L, BIRKMEYER JD, WELCH HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-convetting enzyme inhibitors. Ann Intern Med 131:660-667, 1999
26. CLARK WF, CHURCHILL DN, FORWELL L, et al: To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 162:195-198, 2000
27. EKNOYAN G, BECK GJ, CHEUNG AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002
28. PANIAGUA R, AMATO D, VONESH E, et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307-1320, 2002
29. HEALTH CARE FINANCING ADMINISTRATION: Annual Report. Health Care Financing Administration's End-Stage Renal Disease Clinical Performance Measures Project, Baltimore, MD, Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, 2000, pp 16-17
30. DRUMMOND MF, JEFFERSON TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Econ Eval Working Party. Br Med J 313:275-283, 1996
31. Guidelines for Economic Evaluation of Pharmaceuticals, Canada, 2nd ed, Ottawa. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997
32. EVANS RW, RADER B, MANNINEN DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clin Trim Group. JAMA 263:825-830, 1990
33. LEVIN NW: Quality of life and hematocrit level. Am J Kidney Dis 20:16-20, 1992
34. SCHWAB SJ, OLIVER MJ, SUHOCKI P, et al: Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 59:358-362, 2001
35. WOLFE RA, ASHBY VB, MILFORD EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725-1730, 1999
36. JOHANNESSON M, JONSSON B, KJEKSHUS J, et al: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336:332-336, 1997
37. KAUFMAN JS, REDA DJ, FYE CL, et al: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578-583, 1998
38. FRYBACK DG, LAWRENCE WF, MARTIN PA, et al: Predicting quality of well-being scores from the SF-36: Results from the Beaver Dam Health Outcomes Study. Med Decis Making 17:1-9, 1997
39. CANADIAN ERYTHROPOIETIN STUDY GROUP: Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 11:23-26, 1991
40. PAINTER P, MOORE G, CARLSON L, et al: Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 39:257-265, 2002
41. MCMAHON LP, MASON K, SKINNER SL, et al: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
42. HEALTH CARE FINANCING ADMINISTRATION: Annual Report. Health Care Financing Administration's End-Stage Renal Disease Core Indicators Project, Baltimore, MD, Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, 1998, pp 37-38